Status:
COMPLETED
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Inflammation
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0...
Eligibility Criteria
Inclusion
- CZ: Age between 18 and 65 years (both inclusive)
- A diagnosis of rheumatoid arthritis of at least three months before entry in trial
- Active rheumatoid arthritis (RA)
- Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration
Exclusion
- Known or suspected allergy to trial product or related products
- Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01223911
Start Date
January 1 2011
End Date
February 1 2013
Last Update
February 9 2017
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Prague, Czechia, 128 50
2
Novo Nordisk Investigational Site
Frederiksberg, Denmark, 2000
3
Novo Nordisk Investigational Site
Silkeborg, Denmark, 8600
4
Novo Nordisk Investigational Site
Budapest, Hungary, 1027